Loading
A phase 3 trial of Adagloxad simolenin run by OBI Pharma, Inc, active.
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC is a phase 3 interventional study registered as NCT03562637 by OBI Pharma, Inc, with 575 participants enrolled, started 2018-12-05. Conditions listed: Triple Negative Breast Cancer. No results are recorded here; the registry entry is the source.
Shares Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).